PIQ (ASX) Ann: Study shows diabetes drug improves PromarkerD risk scores

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Hi Owl, Sincere thanks for taking the time to provide a very thorough response to my query. Your insight and knowledge of PIQ is of great benefit to many to less experienced investors in this area.

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

No.	Vol.	Price($)
1	4467	$1.03

No.

Vol.

Price($)

4467

$1.03

Price($)	Vol.	No.
$1.08	10000	1

Price($)

Vol.

No.

$1.08

10000

No.	Vol.	Price($)
1	4467	1.025
2	287465	1.020
1	20000	1.015
7	43463	1.010
2	10726	1.005

No.

Vol.

Price($)

4467

1.025

287465

1.020

20000

1.015

43463

1.010

10726

1.005

Price($)	Vol.	No.
1.075	10000	1
1.080	7000	1
1.105	10000	1
1.140	20000	1
1.150	50000	1

Price($)

Vol.

No.

1.075

10000

1.080

7000

1.105

10000

1.140

20000

1.150

50000

(20min delay)
Last $1.04		Change 0.015(1.46%)		Mkt cap ! $133.5M

Open	High	Low	Value	Volume
$1.03	$1.05	$1.02	$185.9K	180.6K


Last $1.04		Change 0.015 ( 0.00 %)
Open	High	Low	Volume
$1.04	$1.04	$1.02	15283
Last updated 15.53pm 13/05/2024 ?

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Featured News

Magnum to raise US$210M to advance Saudi green pig iron plant

Meet Sun Silver – ASX's newest silver-gold player based in Nevada, USA

Fletcher Building navigates uncertain market dynamics in FY24

Errawarra's pegmatite discovery in WA Pilbara strikes gold on ASX

D3E joins ASX as it hunts natural gas and helium in South Africa

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Featured News

Top Stories

Magnum to raise US$210M to advance Saudi green pig iron plant

Meet Sun Silver – ASX's newest silver-gold player based in Nevada, USA

Fletcher Building navigates uncertain market dynamics in FY24

Errawarra's pegmatite discovery in WA Pilbara strikes gold on ASX

D3E joins ASX as it hunts natural gas and helium in South Africa

Buyers (Bids)

Sellers (Offers)

Featured News